Literature DB >> 24151254

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Adam M Huber1, Gulnara Mamyrova, Peter A Lachenbruch, Julia A Lee, James D Katz, Ira N Targoff, Frederick W Miller, Lisa G Rider.   

Abstract

OBJECTIVE: Because juvenile idiopathic inflammatory myopathies (IIMs) are potentially life-threatening systemic autoimmune diseases, we examined risk factors for juvenile IIM mortality.
METHODS: Mortality status was available for 405 patients (329 with juvenile dermatomyositis [DM], 30 with juvenile polymyositis [PM], and 46 with juvenile connective tissue disease-associated myositis [CTM]) enrolled in nationwide protocols. Standardized mortality ratios (SMRs) were calculated using US population statistics. Cox regression analysis was used to assess univariable associations with mortality, and random survival forest (RSF) classification and Cox regression analysis were used for multivariable associations.
RESULTS: Of 17 deaths (4.2% overall mortality), 8 (2.4%) were in juvenile DM patients. Death was related to the pulmonary system (primarily interstitial lung disease [ILD]) in 7 patients, gastrointestinal system in 3, and multisystem in 3, and of unknown etiology in 4 patients. The SMR for juvenile IIMs overall was 14.4 (95% confidence interval [95% CI] 12.2-16.5) and was 8.3 (95% CI 6.4-10.3) for juvenile DM. The top mortality risk factors in the univariable analysis included clinical subgroup (juvenile CTM, juvenile PM), antisynthetase autoantibodies, older age at diagnosis, ILD, and Raynaud's phenomenon at diagnosis. In multivariable analyses, clinical subgroup, illness severity at onset, age at diagnosis, weight loss, and delay to diagnosis were the most important predictors from RSF; clinical subgroup and illness severity at onset were confirmed by multivariable Cox regression analysis.
CONCLUSION: Overall mortality was higher in juvenile IIM patients, and several early illness features were identified as risk factors. Clinical subgroup, antisynthetase autoantibodies, older age at diagnosis, and ILD are also recognized as mortality risk factors in adult myositis.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24151254      PMCID: PMC4646219          DOI: 10.1002/acr.22212

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  28 in total

1.  Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.

Authors:  Isabelle Marie; Pierre Yves Hatron; Stéphane Dominique; Patrick Cherin; Luc Mouthon; Jean-François Menard; Hervé Levesque; Fabienne Jouen
Journal:  Semin Arthritis Rheum       Date:  2011-11-09       Impact factor: 5.532

2.  Identifying important risk factors for survival in patient with systolic heart failure using random survival forests.

Authors:  Eileen Hsich; Eiran Z Gorodeski; Eugene H Blackstone; Hemant Ishwaran; Michael S Lauer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-11-23

Review 3.  Idiopathic inflammatory myopathies in childhood: current concepts.

Authors:  Adam M Huber
Journal:  Pediatr Clin North Am       Date:  2012-04       Impact factor: 3.278

4.  Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis.

Authors:  V Limaye; P Hakendorf; R J Woodman; P Blumbergs; P Roberts-Thomson
Journal:  Intern Med J       Date:  2012-02       Impact factor: 2.048

5.  Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study.

Authors:  C-F Kuo; L-C See; K-H Yu; I-J Chou; H-C Chang; M-J Chiou; S-F Luo
Journal:  Br J Dermatol       Date:  2011-11-03       Impact factor: 9.302

6.  Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.

Authors:  Dinara Guseinova; Alessandro Consolaro; Lucia Trail; Cristina Ferrari; Angela Pistorio; Nicolino Ruperto; Antonella Buoncompagni; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Eunice Solis-Vallejo; Marcia Bandeira; Vicente Baca; Claudia Saad-Magalhaes; Clovis A Silva; Roberto Barcellona; Luciana Breda; Rolando Cimaz; Romina Gallizzi; Rosaria Garozzo; Silvana Martino; Antonella Meini; Achille Stabile; Alberto Martini; Angelo Ravelli
Journal:  Clin Exp Rheumatol       Date:  2011-02-23       Impact factor: 4.473

7.  Regression trees for predicting mortality in patients with cardiovascular disease: what improvement is achieved by using ensemble-based methods?

Authors:  Peter C Austin; Douglas S Lee; Ewout W Steyerberg; Jack V Tu
Journal:  Biom J       Date:  2012-07-06       Impact factor: 2.207

8.  Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.

Authors:  Xiao Ming Shu; Xin Lu; Yao Xie; Guo Chun Wang
Journal:  BMC Neurol       Date:  2011-11-09       Impact factor: 2.474

9.  Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.

Authors:  Elena Schiopu; Kristine Phillips; Paul M MacDonald; Leslie J Crofford; Emily C Somers
Journal:  Arthritis Res Ther       Date:  2012-01-27       Impact factor: 5.156

10.  The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Authors:  Mona Shah; Gulnara Mamyrova; Ira N Targoff; Adam M Huber; James D Malley; Madeline Murguia Rice; Frederick W Miller; Lisa G Rider
Journal:  Medicine (Baltimore)       Date:  2013-01       Impact factor: 1.889

View more
  29 in total

1.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Authors:  G Esther A Habers; Adam M Huber; Gulnara Mamyrova; Ira N Targoff; Terrance P O'Hanlon; Sharon Adams; Janardan P Pandey; Chantal Boonacker; Marco van Brussel; Frederick W Miller; Annet van Royen-Kerkhof; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 2.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

3.  A 17-year-old girl with facial edema and weakness.

Authors:  Rachel Deschamps; Julie Couture; Aristides Hadjinicolaou; Claire M A LeBlanc
Journal:  Paediatr Child Health       Date:  2018-01-23       Impact factor: 2.253

4.  Environmental factors associated with disease flare in juvenile and adult dermatomyositis.

Authors:  Gulnara Mamyrova; Lisa G Rider; Alison Ehrlich; Olcay Jones; Lauren M Pachman; Robert Nickeson; Lisa G Criscone-Schreiber; Lawrence K Jung; Frederick W Miller; James D Katz
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

5.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 6.  Autoantibodies in myositis.

Authors:  Neil J McHugh; Sarah L Tansley
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 7.  Advances Toward Precision Medicine in Juvenile Dermatomyositis.

Authors:  Jessica Neely; Susan Kim
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

8.  Profile of Pediatric Idiopathic Inflammatory Myopathies from a Tertiary Care Center of Eastern India.

Authors:  Sumantra Sarkar; Tanushree Mondal; Arpan Saha; Rakesh Mondal; Supratim Datta
Journal:  Indian J Pediatr       Date:  2017-03-02       Impact factor: 1.967

Review 9.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

10.  Medications received by patients with juvenile dermatomyositis.

Authors:  Takayuki Kishi; Nastaran Bayat; Michael M Ward; Adam M Huber; Lan Wu; Gulnara Mamyrova; Ira N Targoff; William J Warren-Hicks; Frederick W Miller; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2018-03-28       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.